Recorded $5.8 million in nonrecurring expenses during Q4 related to headcount reductions and asset write-offs during the ...

OPKO reshaped BioReference after selling its oncology assets to Labcorp, trimming headcount ~29% and refocusing on core clinical lab services and the 4Kscore; management expects improved margins and ...

OPKO Health, Inc. OPK delivered a loss per share of 4 cents in the fourth quarter of 2025, against an earnings per share of a cent in the prior-year quarter. Earnings beat the Zacks Consensus ...

Opko Health Inc. (NASDAQ:OPK) is one of the best high-return penny stocks to buy right now. On February 10, analysts at H.C. Wainwright reiterated a Buy rating on Opko Health Inc. (NASDAQ:OPK) and ...

MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial ...

Opko Health’s latest earnings call struck a cautiously optimistic tone, pairing clear strategic progress with near-term financial strain. Management emphasized accelerating ModeX pipeline assets, ...

OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, supported by the potential of RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic ...

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals.